Bionano Genomics (BNGO) Current Deferred Revenue (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Current Deferred Revenue data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 10.39% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 10.39% YoY), and the FY2025 full-year result was $967000.0, down 14.27% from the prior year.
• Current Deferred Revenue advanced to $1.1 million in Q1 2026, from $967000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $1.2 million in Q3 2024 to a low of $783000.0 in Q4 2023.
• A 5-year average of $1.0 million and a median of $1.1 million in 2022 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue jumped 267.77% in 2022 and decreased 17.12% in 2023, its largest moves.
• Tracing BNGO's Current Deferred Revenue over 5 years: stood at $871000.0 in 2022, then decreased by 10.1% to $783000.0 in 2023, then soared by 44.06% to $1.1 million in 2024, then dropped by 14.27% to $967000.0 in 2025, then rose by 16.44% to $1.1 million in 2026.
• Business Quant data shows BNGO's Current Deferred Revenue at $1.1 million in Q1 2026, $967000.0 in Q4 2025, and $1.2 million in Q3 2025.